158 related articles for article (PubMed ID: 8299113)
1. Curative effects of combination therapy with lentinan and interleukin-2 against established murine tumors, and the role of CD8-positive T cells.
Suzuki M; Kikuchi T; Takatsuki F; Hamuro J
Cancer Immunol Immunother; 1994 Jan; 38(1):1-8. PubMed ID: 8299113
[TBL] [Abstract][Full Text] [Related]
2. Reconstitution of anti-tumor effects of lentinan in nude mice: roles of delayed-type hypersensitivity reaction triggered by CD4-positive T cell clone in the infiltration of effector cells into tumor.
Suzuki M; Iwashiro M; Takatsuki F; Kuribayashi K; Hamuro J
Jpn J Cancer Res; 1994 Apr; 85(4):409-17. PubMed ID: 7911123
[TBL] [Abstract][Full Text] [Related]
3. Induction of endogenous lymphokine-activated killer activity by combined administration of lentinan and interleukin 2.
Suzuki M; Higuchi S; Taki Y; Taki S; Miwa K; Hamuro J
Int J Immunopharmacol; 1990; 12(6):613-23. PubMed ID: 2272726
[TBL] [Abstract][Full Text] [Related]
4. Cancer cell progression and chemoimmunotherapy--dual effects in the induction of resistance to therapy.
Hamuro J; Kikuchi T; Takatsuki F; Suzuki M
Br J Cancer; 1996 Feb; 73(4):465-71. PubMed ID: 8595160
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-7 mediates the generation and expansion of murine allosensitized and antitumor CTL.
Jicha DL; Schwarz S; Mulé JJ; Rosenberg SA
Cell Immunol; 1992 Apr; 141(1):71-83. PubMed ID: 1555257
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antimetastatic effects of lentinan and interleukin 2 with pre- and post-operative treatments.
Hamuro J; Takatsuki F; Suga T; Kikuchi T; Suzuki M
Jpn J Cancer Res; 1994 Dec; 85(12):1288-97. PubMed ID: 7852191
[TBL] [Abstract][Full Text] [Related]
7. Generation of specific antitumor cytotoxic T-lymphocytes in monoculture can be inhibited by T-suppressors from tumor-bearing mice.
Lupatov AYu ; Brondz BD
Cancer Biother; 1994; 9(2):123-9. PubMed ID: 7812361
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases.
Yamasaki K; Sone S; Yamashita T; Ogura T
Cancer Immunol Immunother; 1989; 29(2):87-92. PubMed ID: 2785852
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor action of interleukin 2 and its biological activities].
Hamuro J
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 2):2111-8. PubMed ID: 3496854
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and functional heterogeneity of thymic and splenic lymphokine activated killer cells relative to ornithine sensitivity.
Mehrotra P; Bear HD; Susskind BM
Cell Immunol; 1991 Feb; 132(2):451-65. PubMed ID: 1899052
[TBL] [Abstract][Full Text] [Related]
11. Lentinan augments skin reaction induced by bradykinin: its correlation with vascular dilatation and hemorrhage responses and antitumor activities.
Takatsuki F; Namiki R; Kikuchi T; Suzuki M; Hamuro J
Int J Immunopharmacol; 1995 Jun; 17(6):465-74. PubMed ID: 7499022
[TBL] [Abstract][Full Text] [Related]
12. Role of IL-2, IL-4 and IL-6 in the growth and differentiation of tumor-specific CD4+ T helper and CD8+ T cytotoxic cells.
Selvan RS; Nagarkatti PS; Nagarkatti M
Int J Cancer; 1990 Jun; 45(6):1096-104. PubMed ID: 1972141
[TBL] [Abstract][Full Text] [Related]
13. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.
Ciolli V; Gabriele L; Sestili P; Varano F; Proietti E; Gresser I; Testa U; Montesoro E; Bulgarini D; Mariani G
J Exp Med; 1991 Feb; 173(2):313-22. PubMed ID: 1671080
[TBL] [Abstract][Full Text] [Related]
14. Allosensitization in IL-2-containing limiting dilution cultures generates cytotoxic T lymphocytes (CTL) rather than LAK cells reactive with a syngeneic nonimmunogenic murine tumor.
Leshem B; Epstein E; Kedar E
Immunol Lett; 1989 Jan; 20(1):53-8. PubMed ID: 2785493
[TBL] [Abstract][Full Text] [Related]
15. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
Yang ZB
Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
[TBL] [Abstract][Full Text] [Related]
16. Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.
Maas RA; Roest PA; Becker MJ; Weimar IS; Dullens HF; Den Otter W
Immunobiology; 1992 Nov; 186(3-4):214-29. PubMed ID: 1490728
[TBL] [Abstract][Full Text] [Related]
17. Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3653-8. PubMed ID: 9413218
[TBL] [Abstract][Full Text] [Related]
18. Postoperative administration of interleukin-12 significantly enhances the anti-tumor immune response of MBT-2 bladder cancer bearing mice.
Tzai TS; Shiau AL; Wu CL; Tsai YS
Proc Natl Sci Counc Repub China B; 2000 Apr; 24(2):56-62. PubMed ID: 10809081
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
20. Presence of cytotoxic B220+CD3+CD4-CD8- cells correlates with the therapeutic efficacy of lymphoma treatment with IL-2 and/or IL-12.
Masztalerz A; Everse LA; Otter WD
J Immunother; 2004; 27(2):107-15. PubMed ID: 14770082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
